CytoDyn (CYDY) investor relations material

Executive summary

• Focused on clinical development of leronlimab for solid-tumor oncology, with ongoing Phase II trials in colorectal cancer and plans for additional studies in other indications.

• Business strategy includes developing a long-acting version of leronlimab and seeking non-dilutive financing through partnerships.

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses and accumulated deficit of $893.3 million as of August 31, 2025.

Financial highlights

• Net loss of $5.5 million for the quarter ended August 31, 2025, compared to net income of $19.2 million in the same quarter last year, which included a one-time $25.0 million legal settlement.

• Cash and cash equivalents were $9.3 million as of August 31, 2025, down from $11.9 million at May 31, 2025.

• Total current liabilities were $69.4 million, with a stockholders' deficit of $99.5 million.

• Net cash used in operating activities was $2.5 million for the quarter, with minimal cash provided by financing activities.

Outlook and guidance

• Continuation of research and development activities for leronlimab, with significant future expenses expected.

• Ability to fund operations depends on raising additional capital through equity or debt; future funding is uncertain.

• A shareholder vote is scheduled to increase authorized shares, which is critical for future financing.